Indication and clinical use:
Atopic Dermatitis
DUPIXENT® (dupilumab injection) is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
DUPIXENT® can be used with or without topical corticosteroids.
• No dose adjustment is recommended for elderly patients.
• Efficacy and safety of DUPIXENT® in pediatric patients with atopic dermatitis below the age of 6 years have not been established
Asthma
DUPIXENT® (dupilumab injection) is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.
DUPIXENT® is not indicated for relief of acute bronchospasm or status asthmaticus.
• Efficacy and safety in pediatric patients with asthma below the age of 6 years have not been established
Chronic Rhinosinusitis with Nasal Polyposis
DUPIXENT® (dupilumab injection) is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.
• No dose adjustment is recommended for elderly patients.
• Efficacy and safety of DUPIXENT® in pediatric patients with CRSwNP have not been established
Contraindications:
Hypersensitivity to DUPIXENT® or to any ingredient in the formulation or component of the container.
Warnings and precautions:
• Reduction of corticosteroid dosage
• Systemic hypersensitivity reactions
• Elevation of blood eosinophils
• Eosinophilic pneumonia
• Not studied with live vaccines
• Conjunctivitis and keratitis
• Patients with helminth infection
• Patients with concomitant atopic conditions
• Acute asthma symptoms or deteriorating disease
• Pregnant and nursing women
